Voyager Therapeutics Inc Stock Price, News & Analysis

Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced a license option agreement with Novartis for access to its TRACER™ AAV capsids, targeting three CNS applications and options for two additional targets. This deal, alongside a previous Pfizer agreement, extends Voyager's cash runway into 2024 with total upfront payments of $84 million. The company reported a net income of $5.7 million for Q4 2021, improving from a loss in Q4 2020. However, the full year net loss was $71.2 million, primarily due to terminated collaborations. Leadership changes include the appointment of Al Sandrock, Jr. to the Board.

Voyager Therapeutics has entered a significant agreement with Novartis, receiving $54 million upfront and potential milestone payments up to $1.7 billion. The deal allows Novartis access to Voyager's TRACER AAV capsids for three central nervous system (CNS) targets, with options for two more. Voyager could also gain royalties from product sales. The TRACER platform is expected to enhance gene therapy delivery, reducing toxicity risks. This follows a previous collaboration with Pfizer, emphasizing Voyager’s growing capabilities in AAV gene therapy.

Voyager Therapeutics (Nasdaq: VYGR), a gene therapy innovator, has announced its participation in two upcoming virtual investor conferences. The company will present at the SVB Leerink 11th Annual Global Healthcare Conference on Feb. 18, 2022, at 9:20 a.m. ET, and participate in a corporate panel at the Cowen 42nd Annual Health Care Conference on Mar. 9, 2022, at 12:50 p.m. ET. Investors can access the sessions on Voyager's website and replays will be available for at least 30 days.

Voyager Therapeutics (Nasdaq: VYGR) announced the appointment of Alfred W. Sandrock, Jr. to its Board of Directors and the promotion of Robin Swartz to Chief Operating Officer, effective February 7, 2022. Dr. Sandrock, a seasoned drug developer with extensive experience at Biogen, will help steer Voyager's strategies for its TRACER™ AAV capsid screening platform and foster collaborations. Ms. Swartz will oversee several operational departments, marking a strategic leadership change aimed at enhancing the company's gene therapy initiatives.

Voyager Therapeutics (Nasdaq: VYGR) has presented preclinical data showing that its proprietary AAV vector, developed using TRACER™ technology, effectively targets HER2+ breast cancer brain metastases. The findings indicate that intravenous dosing of this vector leads to significant tumor reduction and improved survival rates in mouse models. The anti-HER2 antibody produced through this method achieves high concentrations in cerebrospinal fluid, suggesting potential for effective treatment against CNS tumors. Voyager plans to continue optimizing this innovative gene therapy approach.

Voyager Therapeutics (Nasdaq: VYGR) announced the presentation of preclinical data from its vectorized antibody program at the 26th Annual Society for Neuro-Oncology Meeting on Nov. 19, 2021. The presentation, titled AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis, will be delivered by Dan R. Laks, Ph.D., at 4:15 p.m. ET. This represents a significant advancement in the development of AAV gene therapy technology, aiming to treat severe diseases through innovative approaches.

Voyager Therapeutics has partnered with Pfizer through a licensing agreement to access its TRACER™ capsids for gene therapies targeting neurological and cardiovascular diseases. The deal includes a $30M upfront payment and potential milestone payments of up to $600M. Preclinical results from Voyager's GBA1 gene therapy indicate significant CNS distribution and enzyme activity correction. For Q3 2021, Voyager reported a net loss of $25.1M, down from a net income of $85.6M in Q3 2020, with collaboration revenue decreasing from $117.8M to $1.5M.

Voyager Therapeutics (Nasdaq: VYGR) announced promising preclinical data on its GBA1 gene replacement therapy, showing sustained correction of GCase enzyme activity across multiple brain regions in mice after a single intravenous dose. Results from the virtual Congress of the European Society of Gene and Cell Therapy indicated a 300% to 660% increase in GCase levels, potentially enabling effective treatment for neurological diseases like Gaucher disease and Parkinson’s. The therapy was well-tolerated, showcasing the advantages of blood-brain barrier-penetrant AAV capsids over traditional delivery methods.

Voyager Therapeutics (Nasdaq: VYGR) has entered a partnership with Pfizer, receiving $30 million upfront. The collaboration allows Pfizer to access Voyager's advanced AAV capsids, enhancing drug delivery for gene therapies targeting neurological and cardiovascular diseases. The agreement includes potential exercise fees and milestone payments up to $600 million, along with royalties based on product sales. Voyager retains rights for other applications of its TRACER technology, expected to boost the development of gene therapies and address unmet medical needs.